Literature DB >> 9753294

Prevention of diabetes in NOD mice by a mutated I-Ab transgene.

S M Singer1, R Tisch, X D Yang, H K Sytwu, R Liblau, H O McDevitt.   

Abstract

Susceptibility to the human autoimmune disease IDDM is strongly associated with those haplotypes of the major histocompatibility complex (MHC) carrying DQB1 alleles that do not encode aspartic acid at codon 57. Similarly, in a spontaneous animal model of this disease, the NOD mouse, the genes of the MHC play an important role in the development of diabetes. The DQB1 homolog in NOD mice, I-Ab(g7), encodes a histidine at codon 56 and a serine at codon 57, while all other known I-Ab alleles encode proline and aspartic acid, respectively, at these positions. We therefore mutated the NOD I-Ab allele to encode proline at position 56 and aspartic acid at position 57 and introduced this allele onto the NOD genetic background to study the effect of these substitutions on susceptibility to diabetes. No transgenic mice developed diabetes by 8 months of age, and transgenic mice had markedly reduced lymphocytic infiltration in the pancreas compared with nontransgenic littermates. Furthermore, splenocytes from transgenic mice failed to proliferate or secrete gamma-interferon in response to a panel of beta-cell autoantigens, although the mice did produce beta-cell specific antibodies. Interestingly, the proportion of IgG1 and IgE relative to IgG2a comprising these autoantibodies was much greater in transgenic mice compared with nontransgenic control mice. Finally, T-cells from transgenic mice inhibited the adoptive transfer of diabetes to irradiated recipients. This inhibition was partially reversed by treatment of the recipients with a combination of anti-interleukin (IL)-4 and anti-IL-10 monoclonal antibodies. Thus, a transgenic class II MHC allele encoding aspartic acid at B57 prevents diabetes, in part, by promoting the production of IL-4 and IL-10, which interfere with the effector phase of the diabetic process.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9753294     DOI: 10.2337/diabetes.47.10.1570

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  18 in total

Review 1.  Immunotherapy of immune-mediated diabetes. Present and future.

Authors:  N Maclaren
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

2.  Specificity of peptide selection by antigen-presenting cells homozygous or heterozygous for expression of class II MHC molecules: The lack of competition.

Authors:  Anish Suri; James J Walters; Osami Kanagawa; Michael L Gross; Emil R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-07       Impact factor: 11.205

Review 3.  Genetics of type 1 diabetes.

Authors:  Janelle A Noble; Henry A Erlich
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

4.  The diabetogenic mouse MHC class II molecule I-Ag7 is endowed with a switch that modulates TCR affinity.

Authors:  Kenji Yoshida; Adam L Corper; Rana Herro; Bana Jabri; Ian A Wilson; Luc Teyton
Journal:  J Clin Invest       Date:  2010-04-19       Impact factor: 14.808

Review 5.  Comparative genetics: synergizing human and NOD mouse studies for identifying genetic causation of type 1 diabetes.

Authors:  John P Driver; Yi-Guang Chen; Clayton E Mathews
Journal:  Rev Diabet Stud       Date:  2012-12-28

6.  Position β57 of I-Ag7 controls early anti-insulin responses in NOD mice, linking an MHC susceptibility allele to type 1 diabetes onset.

Authors:  Louis Gioia; Marie Holt; Anne Costanzo; Siddhartha Sharma; Brian Abe; Lisa Kain; Maki Nakayama; Xiaoxiao Wan; Andrew Su; Clayton Mathews; Yi-Guang Chen; Emil Unanue; Luc Teyton
Journal:  Sci Immunol       Date:  2019-08-30

7.  The role of MHC class II molecules in susceptibility to type I diabetes: identification of peptide epitopes and characterization of the T cell repertoire.

Authors:  C C Chao; H K Sytwu; E L Chen; J Toma; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

8.  PD-1 deficiency reveals various tissue-specific autoimmunity by H-2b and dose-dependent requirement of H-2g7 for diabetes in NOD mice.

Authors:  Taku Yoshida; Fang Jiang; Tasuku Honjo; Taku Okazaki
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-25       Impact factor: 11.205

9.  Prevention of type 1 diabetes by gene therapy.

Authors:  Chaorui Tian; Jessamyn Bagley; Nathalie Cretin; Nilufer Seth; Kai W Wucherpfennig; John Iacomini
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

10.  The NeST long ncRNA controls microbial susceptibility and epigenetic activation of the interferon-γ locus.

Authors:  J Antonio Gomez; Orly L Wapinski; Yul W Yang; Jean-François Bureau; Smita Gopinath; Denise M Monack; Howard Y Chang; Michel Brahic; Karla Kirkegaard
Journal:  Cell       Date:  2013-02-14       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.